Insights

Innovative Drug Discovery AQEMIA utilizes advanced physics-based generative AI to develop novel therapeutics, positioning it as a pioneer in precision drug invention. This approach offers opportunities to partner with pharmaceutical companies seeking cutting-edge, differentiated medicines in oncology and major disease areas.

Expanding Market Presence With recent office expansions into London and participation in global healthcare conferences, AQEMIA is increasing its visibility and establishing strategic collaborations. Sales efforts can leverage these growth initiatives to introduce complementary biotech or pharma products and services.

Strong Funding Momentum Having secured over $100 million in cumulative funding, AQEMIA demonstrates robust investor confidence and financial backing. This financial health indicates capacity for scaling operations, making it a credible partner for joint ventures and collaborative research initiatives.

Emerging Industry Leader AQEMIA's recognition within programs like French Tech 120 and memberships in biotech associations highlight its status as an innovative and influential player. This positioning provides opportunities to target their strategic collaborations or explore co-marketing opportunities within the biotech ecosystem.

Technology-Driven Innovation By leveraging advanced AI tools like TensorFlow, GROMACS, and NoSQL, AQEMIA is at the forefront of technological adoption in biotech. Sales teams can focus on offering complementary AI solutions, data management platforms, and computational tools to support their R&D process.

AQEMIA Tech Stack

AQEMIA uses 8 technology products and services including CIM Technologies, Google Hosted Libraries, GROMACS, and more. Explore AQEMIA's tech stack below.

  • CIM Technologies
    Cad & Graphics
  • Google Hosted Libraries
    Content Delivery Network
  • GROMACS
    Data Management
  • NoSQL
    Database
  • git
    Development
  • GitHub Actions
    Devops
  • TensorFlow
    Machine Learning
  • Google Tag Manager
    Tag Management

Media & News

AQEMIA's Email Address Formats

AQEMIA uses at least 1 format(s):
AQEMIA Email FormatsExamplePercentage
First.Last@aqemia.comJohn.Doe@aqemia.com
49%
First.Middle@aqemia.comJohn.Michael@aqemia.com
1%
First@aqemia.comJohn@aqemia.com
1%
First.Last@aqemia.comJohn.Doe@aqemia.com
49%

Frequently Asked Questions

Where is AQEMIA's headquarters located?

Minus sign iconPlus sign icon
AQEMIA's main headquarters is located at 1 Boulevard Pasteur Paris, Île-de-france 75015 France. The company has employees across 2 continents, including EuropeAfrica.

What is AQEMIA's official website and social media links?

Minus sign iconPlus sign icon
AQEMIA's official website is aqemia.com and has social profiles on LinkedInCrunchbase.

What is AQEMIA's SIC code NAICS code?

Minus sign iconPlus sign icon
AQEMIA's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does AQEMIA have currently?

Minus sign iconPlus sign icon
As of March 2026, AQEMIA has approximately 79 employees across 2 continents, including EuropeAfrica. Key team members include Ceo & Co-Founder: M. L.Ceo And Co-Founder: M. L.Coo And Co-Founder: E. M. R.. Explore AQEMIA's employee directory with LeadIQ.

What industry does AQEMIA belong to?

Minus sign iconPlus sign icon
AQEMIA operates in the Biotechnology Research industry.

What technology does AQEMIA use?

Minus sign iconPlus sign icon
AQEMIA's tech stack includes CIM TechnologiesGoogle Hosted LibrariesGROMACSNoSQLgitGitHub ActionsTensorFlowGoogle Tag Manager.

What is AQEMIA's email format?

Minus sign iconPlus sign icon
AQEMIA's email format typically follows the pattern of First.Last@aqemia.com. Find more AQEMIA email formats with LeadIQ.

How much funding has AQEMIA raised to date?

Minus sign iconPlus sign icon
As of March 2026, AQEMIA has raised $7.4M in funding. The last funding round occurred on Apr 01, 2025 for $7.4M.

When was AQEMIA founded?

Minus sign iconPlus sign icon
AQEMIA was founded in 2019.

AQEMIA

Biotechnology ResearchÎle-de-france, France51-200 Employees

AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data.

We are building a rapidly expanding portfolio of proprietary programs, alongside collaborations with top pharmaceutical companies. Multiple discovery successes are already achieved, with lead programs progressing through in vivo optimization.

AQEMIA is part of the French Tech 120 program, which supports the most promising scale-ups in France with global impact potential. 

AQEMIA is member of the BioIndustry Association (BIA) and the Knowledge Quarter in London.

AQEMIA is based in Paris (HQ) and London.

We are growing and hiring! Discover our opportunities here: https://jobs.lever.co/aqemia.com

Discover the roles and behind-the-scenes at AQEMIA: https://www.welcometothejungle.com/fr/companies/aqemia

Section iconCompany Overview

Headquarters
1 Boulevard Pasteur Paris, Île-de-france 75015 France
Website
aqemia.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
51-200

Section iconFunding & Financials

  • $7.4M

    AQEMIA has raised a total of $7.4M of funding over 6 rounds. Their latest funding round was raised on Apr 01, 2025 in the amount of $7.4M.

  • $1M$10M

    AQEMIA's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $7.4M

    AQEMIA has raised a total of $7.4M of funding over 6 rounds. Their latest funding round was raised on Apr 01, 2025 in the amount of $7.4M.

  • $1M$10M

    AQEMIA's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.